```json
{
"content": [
{
"type": "paragraph",
"content": "The hERG Screening market outlook is underpinned by a robust regulatory mandate that makes ion-channel liability testing non-negotiable, translating into resilient, recession-proof demand. Market attractiveness remains high because a single hERG-related late-stage failure can erase >$500 M in development spend, so sponsors readily adopt higher-throughput, more predictive platforms. Competitive intensity is moderate: four platform developers hold >60 % share, yet nimble AI-first entrants are resetting price-performance expectations and forcing incumbents to bundle data-analytics or risk disintermediation. The long-term trajectory is mid-teens CAGR, driven by biologics and gene-therapy safety testing that extends hERG assays beyond small molecules."
},
{
"type": "paragraph",
content: "Innovation is converging on human iPSC-derived cardiomyocyte systems and label-free impedance; these next-gen models compress timelines by 30 % and cut animal use, aligning with 3Rs pressure. Demand–supply is balanced short-term, but capacity for GLP-certified high-throughput services tightens as CDMOs outsource; expect spot price inflation of 5–7 %. Key risks: regulatory harmonization delays, especially in China and India, and liability if AI-predicted ‘safe’ molecules later show TdP in the clinic—scenarios that could shift the market back to gold-standard manual patch clamp."
}
]
}
```
